What is the main risk associated with the use of Ziprasidone?

The primary concern associated with the use of Ziprasidone is QT prolongation. This antipsychotic medication, which is commonly used for the treatment of schizophrenia and bipolar disorder, has been shown to affect the cardiac repolarization process, leading to an extended QT interval on an ECG. This prolongation can increase the risk of developing life-threatening arrhythmias, such as Torsades de Pointes, particularly in patients who may already have other risk factors (e.g., electrolyte imbalances, concomitant use of other QT-prolonging medications, or pre-existing cardiac conditions).

Monitoring of the ECG, especially at the beginning of treatment or when doses are adjusted, is crucial for patients receiving Ziprasidone due to this specific risk. Adequate education about the signs and symptoms of arrhythmias should also be provided to patients.

While weight gain is a common side effect associated with many antipsychotics, Ziprasidone is generally considered to have a lower risk for this issue compared to others, such as olanzapine or clozapine. Severe neutropenia is more commonly associated with clozapine, and low risk for extrapyramidal symptoms (EPS) is also noted with Ziprasid